Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645924 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL6177344 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL1556431 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL19949394 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL6177296 | 1.00 | CCKBR (0.54) | CCKBRCCKAR | |
| Water SCHEMBL1394819 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| Water SCHEMBL29806115 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| Water SCHEMBL1394812 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL6177951 | 0.99 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL6177958 | 0.99 | CCKBR (0.53) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318314-A1 | ANTITUMOR AGENT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-08 | — | — | US | claimed |
| US-20170151256-A1 | ANTITUMOR AGENT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-01 | — | — | US | claimed |
| EP-2305654-B1 | THERAPEUTIC AGENT FOR CANCER PAIN | ZERIA PHARM CO LTD (JP) | 2015-10-14 | — | — | EP | claimed |
| US-20150038495-A1 | THERAPEUTIC AGENT FOR PAIN | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-05 | — | — | US | claimed |
| EP-2305654-A1 | THERAPEUTIC AGENT FOR PAIN | Zeria Pharmaceutical Co., Ltd. (JP) | 2011-04-06 | — | — | EP | claimed |
| US-20110059956-A1 | THERAPEUTIC AGENT FOR PAIN | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-10 | — | — | US | claimed |
| US-20100143366-A1 | ANTITUMOR AGENT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | US | claimed |
| US-20100086553-A1 | ANTITUMOR AGENT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-04-08 | — | — | US | claimed |
| EP-1839662-B1 | ANTITUMOR AGENT | ZERIA PHARM CO LTD (JP) | 2010-03-24 | — | — | EP | claimed |
| US-20080161293-A1 | Antitumor Agent | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1839662-A1 | ANTITUMOR AGENT | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-10-03 | — | — | EP | claimed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | claimed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | claimed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | claimed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885 |
| US-20110059956-A1 | THERAPEUTIC AGENT FOR PAIN | OPRK1, OPRD1, OPRL1 | CCKBR 466/4885CCKAR 85/4885 |
| US-20100086553-A1 | ANTITUMOR AGENT | MEN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GABRA1 | CCKBR 135/4885CCKAR 90/4885 |
| US-20180318314-A1 | ANTITUMOR AGENT | MEN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GABRA1 | CCKBR 135/4885CCKAR 90/4885 |
| US-20080161293-A1 | Antitumor Agent | MEN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GABRA1 | CCKBR 135/4885CCKAR 90/4885 |
| US-20150038495-A1 | THERAPEUTIC AGENT FOR PAIN | OPRK1, OPRD1, OPRL1 | CCKBR 466/4885CCKAR 85/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885 |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | CCKBR 1/4885CCKAR 2/4885 |
| US-20170151256-A1 | ANTITUMOR AGENT | MEN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GABRA1 | CCKBR 135/4885CCKAR 90/4885 |
| US-20100143366-A1 | ANTITUMOR AGENT | MEN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GABRA1 | CCKBR 135/4885CCKAR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.